This Iranian trial aimed to assess the effect of oral high-dose vitamin D intake on the production of a pro-inflammatory substance (interleukin-17, IL-17) in multiple sclerosis (MS) patients. 94 patients diagnosed with MS were therefore divided into two groups. One group received 50,000 IU (1250 µg) of vitamin D3 every five days for 12 weeks. The other group was given a placebo. The levels of IL-17 were measured at the beginning of the study and after 12 weeks. This study showed that the pro-inflammatory IL-17 significantly changed in these patients after receiving high doses of vitamin D3. More details can be found in the study.
Toghianifar et al.